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Introduction
Tumor growth is a very complex process including
mutations of suppressor genes and oncogenes, uncon-
trolled proliferation and resistance to apoptosis, migra-
tion and invasion of surrounding tissues and distant
organs [1]. Several surface receptors including growth
factor, cytokine and chemokine receptors and their lig-
ands play a role in facilitating tumor growth [1]. 
The major function of chemokines and chemokine
receptors is to facilitate the migration of various cells
types particularly of hematopoietic origin [2]. They are
responsible for migration of immunocompetent cells
to the sites of inflammation and pathogen invasion [2].
In some cases they can also provide the entrance for
pathogens into our body [3].
Chemokines and chemokine receptors are very
important in cancerogenesis and metastasis. Recent
studies have shown that activation of chemokine
receptors by their ligands can stimulate tumor prolifer-
ation, resistance to apoptosis and tumor cells move-
ment [4]. One of the most important and the best stud-
ied receptor involved in these processes is CXCR4, a
member of the family of G-protein-coupled seven-
span transmembrane receptors. CXCR4 plays a role in
metastasis of breast cancer [5], lung cancer [6], neu-
roblastoma [7] and rhabdomyosarcoma [8]. Its
CXCR4 ligand, stromal derived factor 1 (SDF-1), is
constitutively expressed in various tissues and it is
responsible for directing tumor cells invasion and
metastasis [4]. Its expression can be enhanced by
chemo- and radiotherapy and lead to even faster
spreading of tumor cells [4]. CXCR4 has long been
considered as the unique receptor for SDF-1 and the
only mediator of SDF-1-induced biological effects [9].
However, recently, SDF-1 was shown to bind with a
high affinity to the orphan receptor RDC1, later
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renamed CXCR7 [10,11]. The affinity of SDF-1 to
CXCR7 is approximately ten fold higher than the
affinity of SDF-1 to CXCR4 [12]. 
CXCR7 is expressed on tumor cell lines [13,14],
activated endothelial cells [14], and early fetal liver
cells [11]. Despite its high affinity to SDF-1, the role
of CXCR7 in SDF-1-dependent cell motility, chemo-
taxis and calcium flux has been a subject of debate.
Recent studies confirmed a critical role of CXCR7 in
tumor vascular formation, angiogenesis and cell pro-
liferation and survival [12]. Recently, it has been
shown that CXCR7 forms functional heterodimers
with CXCR4 and influences SDF-1 mediated CXCR4
signaling [15]. Besides binding to SDF-1, CXCR7 is
also a receptor for inducible T cell alpha chemoattrac-
tant (I-TAC) [11]. I-TAC also binds to CXCR3
chemokine receptor. CXCR3 is preferentially
expressed on the surface of Th1 T cells. CXCR3 has
been localized to infiltrating effector T cells of the Th1
type in a wide variety of human inflammatory diseases
[16]. Through CXCR3, I-TAC directs migration of
Th1 lymphocytes [16] and it has been shown to influ-
ence epidermal maturation during wound healing [17]. 
Cervical carcinoma (CC) is one of the major caus-
es of mortality and morbidity among women suffering
from cancer in low and medium income countries
including Poland [18]. It is mostly due to the late diag-
nosis at the advanced stage of the disease, often with
distant metastasis [18]. Metastasis are primarily to
lungs, liver, bones and bone marrow. Rhabdomyosar-
coma (RMS), the most common pediatric soft tissue
sarcoma can be divided into two major subtypes
embryonal RMS (ERMS) and alveolar RMS (ARMS))
based on histopathological and molecular features
[19]. ARMS expresses fusion proteins PAX3-FKHR
and PAX7-FKHR [20, 21] and the presence of these
fusion genes has been shown to correlate with the high
risk of relapse, metastasis (often to bone marrow) and
overall worse prognosis [22-24]. Glioblastoma multi-
forme (GMB) is a rare tumor with incidence of 2 cases
per 100 000 people per year [25]. However, among
tumors developed in nervous system it accounts 25%
of all malignant tumors [26]. The survival rate of GMB
patients is very low, approximately 30% at one year
and less than 3% at five years [26]. 
Since the role of CXCR7 and CXCR3 receptors
during carcinogenesis and metastasis is still largely
unknown, the purpose of this study was to evaluate the
presence and function of these receptors and their lig-
and, I-TAC, in cervical carcinoma, rhabdomyosarco-
ma and glioblastoma multiforme models.
Materials and methods
Cell lines. Cervical carcinoma cell lines (CC): HTB-34, HTB-35
and HeLa, were maintained in MEM supplemented with 10% FBS.
Rhabdomyosarcoma cell lines (RMS): RH30, RH18, RH28,
CW9019, SMS-CTR, RD were kindly gifted by M.Z. Ratajczak
(University of Louisville, KY, USA) and maintained in DMEM
supplemented with 10% FBS. Glioblastoma cell lines (GMB):
LN18, LN229, T98G were generously provided by K. Reiss (Tem-
ple University, Philadelphia, USA) and were maintained in DMEM
supplemented with 10% FBS. All the cells were cultured at 37°C,
5% CO2, 95% humidity. They were split twice a week with medi-
um change. 
Flow cytometry. The presence of CXCR7 and CXCR3 receptors
on the surface of target cells were demonstrated by staining with
rabbit anti-CXCR7 primary antibody (Abcam, Cambridge, MA,
USA), anti-rabbit-FITC secondary antibody (Becton Dickinson,
Franklin Lakes, NJ, USA) and mouse anti-CXCR3-APC (Becton
Dickinson, Franklin Lakes, NJ, USA) and analyzed by FACS.
Briefly, 1×105 cells were suspended in 100 µl of staining buffer
(PBS, 2% FBS) and rabbit or mouse Ab was added. Next, cells
were incubated in the dark for 30 min. at 4°C. The stained cells
were washed, and in the case of CXCR7 the secondary antibody
was added and the staining procedure was repeated. After staining,
cells were collected using FACSCanto cytometer (Becton Dickin-
son, San Jose, CA, USA) and analyzed with FACS Diva software
(Becton Dickinson, San Jose, CA, USA).
RNA extraction and reverse transcription. Total RNA was
extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany) fol-
lowed by DNAse treatment (Promega, Madison, WI, USA). The
reverse polymerase transcription was performed using MMLV
reverse transcriptase (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer's protocol.
Quantitative real time PCR analysis. The expression of CXCR7
was determined by quantitative real time PCR analysis on ABI
PRISM 7300 Sequence Detection System (Applied Biosystems,
Foster City, CA) using a commercially available PCR Master Mix.
The primers/probe set for CXCR7 (Hs00604567_m1) was used.
The mRNA expression level for all samples was normalized to the
housekeeping gene GAPDH (Hs99999905_m1). All
primers/probes sets were from Applied Biosystems (Foster City,
CA, USA).
Western blot. Western blots were done on extracts prepared from
cells stimulated with I-TAC, SDF-1 β or both ligands together (I-
TAC 10 ng/ml and SDF-1β 10 ng/ml) as described previously [27].
Briefly, the cells were lysed (for 10 min) on ice in M-Per lysing
buffer (Thermo Scientific, Rockford, IL, USA) containing protease
and phosphatase inhibitors (Sigma, St. Luis, MO, USA). The pro-
teins were separated on a 10% SDS-PAGE gel and transferred to a
PVDF membrane. The phosphorylation of intracellular pathway
proteins was examined after stimulation with ITAC or SDF-1 for 5
min. The phosphorylation of 44/42 MAPK and AKT proteins were
detected by phospho-specific mouse p42/44 MAPK and rabbit
AKT antibody (Cell Signaling, Danvers, MA, USA) and HRP-con-
jugated goat anti-rabbit and anti-mouse secondary antibody (Santa
Cruz Biotech, CA, USA). The membranes were developed with an
enhanced chemiluminescence (ECL) reagent (Thermo Scientific,
Rockford, IL, USA), dried, and subsequently exposed to the
HyperFilm (Amersham Life Sciences, Buckinghamshire, UK). An
equal loading in the lanes was evaluated by probing with an anti
GAPDH antibody (Cell Signaling, Danvers, MA, USA). For den-
sitometry analysis blots were scanned and analyzed with Kodak
Molecular Imaging Software, Version 4.5
Cell Proliferation/Survival Assay. The cell proliferation/survival
assay was performed using CellTiter 96 Aqueous One Solution Kit
accordingly to the manufacturer's recommendations (Promega,
Madison, WI, USA). Cells (CC: HTB-35, RMS: RH30 and GMB:
LN229), were seeded in 96-well plates at 2×103/well in 200 µl of
105I-TAC, CXCR7 and CXCR3 in tumor biology
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2010:48(1): 105 (104-111) 
10.2478/v10042-008-0091-7
DMEM medium containing 0.5% BSA (control), 10% FBS (posi-
tive control), 0.5% BSA and I-TAC (1 or 10 ng/ml). After 24, 48,
72 and 96 hours, 20 µl of CellTiter 96 Aqueous One Solution
reagent were added to each well and plates were incubated for 3
hours. Subsequently, plates were read at 490 nm using the EL×800
Universal Microplate Reader (Bio-tek Instruments, Highland Park,
USA) and analyzed with KC4 v3.0 with PowerReports software.
Each experiment was repeated three times and each concentration
was in triplicates.
Chemotaxis assay. The directional movement of cells toward I-
TAC (R&D System, Minneapolis, MN, USA) and SDF-1β
(PeproTech, Rocky Hill, NJ, USA) gradient was evaluated using
modified Boyden's chamber with 8-µm pore polycarbonate mem-
brane inserts (Costar Transwell; Costar-Corning, Lowell, MA,
USA). Cells detached with 0.25% trypsin were seeded into the
upper chamber of an insert at the density of 2.5×104 in 100 µl. The
lower chamber was filled with pre-warmed medium containing I-
TAC (1, 10, 100 ng/ml) and SDF-1β (10 ng/ml) or both ligands
together (I-TAC 10 ng/ml and SDF-1β 10 ng/ml). 0.5% BSA
DMEM medium was used as a negative control. After 24 hours,
inserts were removed from the transwells and the cells were fixed
with methanol. The cells that did not migrate were scraped off with
cotton wool from the upper membrane and the cells that had trans-
migrated to the lower side of the membrane were stained with
Wright solution and counted under high power field (HPF) with
inverted microscope. Five fields were counted each time and the
mean number of cells per HPF was calculated.
Results
The expression of CXCR7 by rhabdomyosarcoma,
cervical carcinoma and glioblastoma cells 
The expression of CXCR7 in CC, GMB and RMS cell
lines was analyzed using real-time RT-PCR and flow
cytometry. All CC cell lines expressed CXCR7 at
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Fig. 1. Expression of CXCR7 by various tumors cell lines. Using real time RT-PCR (upper panels) and cytofluorymetric analysis (lower
panels) expression of CXCR7 receptor has been studied in A – cervical carcinoma cell lines, B – glioblastoma and C – rhabdomyosarco-
ma. For mRNA analysis experiments were repeated twice and average data with SD are shown. For FACS analysis experiments were
repeated also twice and representative staining is shown; [AU] arbitraty units.
mRNA level (Fig. 1A-upper panel). The surface
expression of CXCR7 by CC cell lines was very high
(HeLa – 87%, HTB-34 – 82%, HTB35 – 98%) (Fig.
1A – lower panel). GMB cell lines also expressed
mRNA for the receptor (Fig. 1B-upper panel). Howev-
er, surface expression varied from low for LN18 (25%)
to high T98G (72%) and LN229 (83%) (Fig. 1B-lower
panel). We also looked for the expression of mRNA
and proteins in RMS cell lines. In the case of embry-
onal subtype mRNA was detected in one cell line (RD)
(Fig. 1C-upper panel) and the surface staining revealed
very low expression of CXCR7. At the same time
mRNA for CXCR7 was detected in all four alveolar
cell lines and the surface expression was high (RH18 –
78.2%, RH28 – 87.9%, RH30 – 88.9%, CW9019 –
88.2%) (Fig. 1C-lower panel).  
The expression of CXCR3 by rhabdomyosarco-
ma, cervical carcinoma and glioblastoma cells 
Next, we checked the expression of CXCR3, the sec-
ond I-TAC receptor. CC cell lines had low expression
of CXCR3: HeLa – 10%, HTB-34 – 7% and HTB-35
– 3% (Fig. 2A). GMB cell lines also expressed
CXCR3 receptor (T98G – 6%, LN18 – 15%) (Fig.
2B). RMS cell lines expressed CXCR3 at the low level
with higher expression seen for ERMS cell lines (Fig.
2C).   
The activation of intracellular pathways by 
I-TAC
We tested the ability of CXCR7 and CXCR3 ligand, I-
TAC, to activate various intracellular pathways. Cell
lines were starved for 24 hours and subsequently stim-
ulated with 10 ng/ml of I-TAC. CC cell lines had dif-
ferent pattern of AKT and MAPK phosphorylation. In
CC cell line, HTB-35, I-TAC caused activation of
MAPK only after 10 min of stimulation with no sign
of AKT activation. However in Hela cell line I-TAC
stimulated phosphorylation of AKT and MAPK. In the
case of AKT kinase we observed strong phosphoryla-
tion after 2 minutes, with no sign after 5 minutes.
Again, after 10 minutes of stimulation strong phos-
phorylation, lasting until 30 minutes with visible
increase, was observed. A pattern of phosphorylation
was different for MAPK kinase with the strongest
phosphorylation observed after 2 minutes and gradual-
ly diminishing after 10 minutes of stimulation (Fig.
3A). In the case of GMB and RMS cell lines (LN18
and RH30, respectively) maximum AKT kinase acti-
vation was observed 2 minutes after stimulation and
gradually decreased (Fig. 3A). The effect of I-TAC on
tumor cells proliferation was also measured. Cells
were seeded in medium containing 0.5% BSA and two
concentrations of I-TAC 1 ng/ml and 10 ng/ml. Medi-
um containing 10% FBS was used as a positive con-
trol. We did noticed any changes in proliferation rate
regardless of I-TAC concentration used (Fig. 3B). In
the case of HTB-35 cell line, cells proliferated to the
same extend in medium with 0.5% BSA alone and in
medium supplemented with 10% FBS. 
Co-stimulation of tumor cell migration and
intracellular signaling by I-TAC and SDF-1β
The activation of tumor cells migration by I-TAC was
tested using chemotaxis assay. HeLa cells were seeded
in modified Boyden chamber and subjected to the gra-
dients of I-TAC, SDF-1β and both ligands together. 
I-TAC alone did not stimulate the migration of tumor
cells at concentrations of 1 ng/ml and 10 ng/ml. The
low induction of migration was observed at 100 ng/ml
(Fig. 4A). At the same time cells subjected to SDF-1β
gradient showed migration toward concentration of 
10 ng/ml and 100 ng/ml (Fig. 4A) as observed previ-
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Fig. 2. Expression of CXCR3 by various tumors cell lines. Using cytofluorymetric analysis expression of CXCR3 receptor has been stud-
ied in A – cervical carcinoma cell lines, B – glioblastoma and C – rhabdomyosarcoma. Experiments were repeated twice and representa-
tive staining is shown.
ously [28]. However, we noticed that preincubation of
HeLa cells with 10 ng/ml of I-TAC and subsequent stim-
ulation of migration by low concentration dose of SDF-
1β 10 ng/ml caused stronger migration of tumor cells
(Fig. 4A) suggesting that I-TAC might play an important
role in sensitizing tumor cells to SDF-1β gradient.  
Next, we looked at the co-activation of intracellular
signaling by I-TAC and SDF-1β. Phosphorylation of
MAPK after stimulation with low (10 ng/ml) and high
(100 ng/ml) concentrations of I-TAC and SDF-1β or
their combination were studied. We observed that both
concentrations of I-TAC did not induce MAPK phos-
phorylation after 5 minutes (Fig. 4B) similarly to the
data presented in Fig. 3. At the same time SDF-1β
stimulated phophorylation of MAPK at both concen-
trations (Fig. 4B). However, when I-TAC and SDF-1β
where added together at the low concentration (10
ng/ml) the activation of MAPK was significantly high-
er when compared to the stimulation with each ligand
separately and was similar to the stimulation seen after
the high concentration of SDF-1β (Fig. 4B).   
Discussion
In this study we investigated the expression of I-TAC
binding receptors, CXCR7 and CXCR3, on human
cervical carcinoma, glioblastoma and rhabdomyosar-
coma cell lines. We showed that CXCR7 is highly
expressed on CC, GMB and more aggressive alveolar
subtype of RMS. CXCR3 was also expressed on tumor
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Fig. 3. Analysis of intracellular pathways activation and assessment of tumor cells proliferation after I-TAC stimulation. Panel A – HTB-
35, HeLa, LN18 and RH30 cell lines were stimulated with I-TAC (100 ng/ml) for 2, 5, 10 and 30 min. The phosphorylation of AKT and
MAPK kinases has been assessed. GAPDH detection was used as a control of equal loading of the samples. Experiments were done twice
with similar results. Panel B – Tumor cells were grown in medium containing 0.5% BSA, medium containing 0.5% BSA supplemented
with 1 ng/ml and 10 ng/ml of I-TAC. As a positive control medium containing 10% FBS was used. After 24, 48, 72 and 96 hours the pro-
liferation rate was measured using CellTiter 96 Aqueous One Solution. No changes in tumor cells proliferation were noticed. Experiment
was repeated three times with similar results and representative data are shown. 
cell lines but at lower level or was not expressed at all
in the case of ARMS. We also showed that I-TAC was
able to activate signal transduction pathways responsi-
ble for tumor growth and survival. Our data indicate
that CXCR7 and, to lower extend, CXCR3 may play a
role in various aspects of the biology of human CC,
GMB and RMS. 
CXCR7 was expressed at the various levels on the
surface of different tumor types. The highest expres-
sion was seen on alveolar subtype of RMS. All ARMS
cell lines expressed CXCR7 at a high level. At the
same time ERMS cells expressed this receptor at a
very low level. Since ARMS is considered to be more
aggressive and metastatic than ERMS [22-24], thus the
difference in expression patterns between RMS sub-
types could be a result of the more aggressive pheno-
type of ARMS or it could be also the cause of that phe-
notype. This distinction needs further analysis. Since
ARMS also expresses CXCR4 at higher level than
ERMS it is also possible that, according to recent pub-
lications, CXCR7 forms heterodimers with CXCR4
and its expression is necessary for CXCR4 signaling
regulation [15]. We also studied the expression of
CXCR3 in RMS and we found that it is inversely cor-
related with the expression of CXCR7. More aggres-
sive ARMS subtype expressed CXCR3 only at a very
low level or did not expressed CXCR3 at all. At the
same time ERMS subtype had much higher expression
of this receptor. The meaning of this pattern of expres-
sion is unknown and will need further studies using
specific inhibitors or RNA interference.
Several chemokine receptors have been shown to
play a role in biology of GMB. The expression of
CCL3L1, CCR3 and CCR5 was evaluated in tumor tis-
sues and their up-regulation in approximately 60% of
GMB tumor samples was shown in comparison to
lower-grade gliomas [29]. CCL3L1 overexpression in
GMB cell lines stimulated proliferation of tumor cells
[29]. The activation of CXCR2 by IL-8 has been
shown to induce the migration of tumor-associated
brain endothelial cells and promote angiogenesis [30].
CXCR1 and CXCR2 has been shown to be expressed
in glioma specimens at the various stages including
GMB [30]. In the same study the expression of
CXCR3 and CXCR4 receptors has also been detected.
The expression of CXCR4 was attributed to the inva-
sive behavior of GMB cells [31] and its activation was
shown to stimulate the proliferation of GMB cells
[32]. In this study we confirmed the expression of
CXCR3 by GMB cell lines and for the first time we
showed the expression of CXCR7 by GMB cell lines
both at mRNA and protein level. 
The role of chemokine receptors in biology of CC
has not been studied in great details. Recently, our
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Fig. 4. Stimulation of tumor cell migration and
intracellular signaling by ITAC and SDF-1β.
Panel A – Stimulation of HeLa cells migration
by I-TAC and SDF-1 was tested using chemo-
taxis assay. Ligands were used at low dose (1,
10 ng/ml), high dose (100 ng/ml) and both at
10 ng/ml. Experiments were repeated twice
and average data with SD are shown. Panel B
– Activation of MAPK kinase after 10 ng/ml
and 100 ng/ml of I-TAC and SDF-1 was eval-
uated. Cells were stimulated for 5 minutes
with each ligand alone and with both I-TAC
and SDF-1 at low dose. GAPDH was used as
the loading control. In order to study the syn-
ergistic effect of low doses, a chemokines
densitometry analysis was performed. Exper-
iment was done twice and representative blot
with densitometry is shown. 
group has shown that SDF-1-CXCR4 axis play an
important role in stimulating invasive behavior of CC
[28]. It was later confirmed by papers showing an
important role of SDF-1-CXCR4 axis in lymph node
metastasis of this tumor [33-35]. Here, we found that
CC cell lines express CXCR7 and CXCR3 receptors.
However, the expression of CXCR7 was higher and
more uniform. It might suggest an important role of
CXCR7 in tumorigenesis of CC particularly in the
light of resent observation that CXCR7 and CXCR4
can form heterodimers with stronger affinity to SDF-1.
CC cells expressed CXCR3 at low level what might
suggest minor role of this receptor in cervical cancer
development and progression.
Since chemokines and their receptors has been impli-
cated in the activation of various intracellular pathways
and stimulation of cell migration [4, 8, 28], in this study
we have looked at the activation of intracellular path-
ways (such as PI3K-AKT, RAS-MAPK) and migration
after I-TAC stimulation. We found that I-TAC is able to
stimulate the phosphorylation of MAPK kinases path-
ways involved in cell proliferation and protection from
apoptosis. However, the activation of growth promoting
pathways did not correlate with increased proliferation
level. Cells stimulated with I-TAC at two different con-
centrations did not responded with higher proliferation
rate in comparison to control. It might suggest that in
tumor cells used in our study signals transmitted through
CXCR7 receptor do not activate growth program. This
data are in agreement with previous publication showing
that stimulation of tumor cells with I-TAC did not affect
the proliferation rate in multiple myeloma cells, howev-
er in that case the activation signals were transmitted
through CXCR3 receptor [36].  
Moreover, stimulation of tumor cells with a low
dose of SDF-1β and I-TAC resulted in the enhanced
activation of MAPK kinase in comparison to the stim-
ulation with SDF-1β or I-TAC alone. Recent data has
suggested that binding of I-TAC to CXCR7 receptor
can play a role in modulating proliferation and survival
[10-12]. CXCR7 was also shown to stimulate migra-
tion of cells during embryogenesis of zebra fish [37].
However, the data on tumor cells migration are not
clear. In this study we have shown that I-TAC only
slightly stimulates migration of tumor cells. However,
it can enhance the migration of tumor cells toward
SDF-1β gradient.
In summary, our data showed that cervical carcino-
ma, glioblastoma and rhabdomysarcoma express
CXCR3 and CXCR7 receptors on their surface. More-
over, tumor cells stimulated by CXCR3/CXCR7 lig-
and, I-TAC, activated the intracellular pathways
engaged in cell proliferation and protection from apop-
tosis. I-TAC can also sensitize tumor cells to SDF-1β.
Thus, I-TAC/CXCR7 and I-TAC/CXCR3 axis might
be potential targets for developing antitumor therapy.
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